Uk.ResellerClub Launches New Promotion Offering Free .CO.UK Domains With Hosting Packages

LONDON, May 10, 2013 /PRNewswire/ --  Web Presence products provider Uk.ResellerClub have...

Wirecard Gains SriLankan Airlines As A New Customer In Asia

MUNICH, Germany, April 30, 2013 /PRNewswire/ -- Wirecard AG, provider of a globally accepted payment...

Global Payments Continues Focus On Mobile Payments In The UK

LONDON, March 28, 2013 /PRNewswire/ -- Global Payments is further strengthening its mobile payment...

Induced Pluripotent Stem Cell Industry Report

Stem cell research and experimentation has been in process for well over five decades and they...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »


Oxford BioMedica plc, a gene-based biopharmaceutical company, and Cardiff University announced a Phase II trial to assess the safety and immunological activity of TroVax(R), a therapeutic vaccine for patients with inoperable metastatic colorectal cancer (CRC). The study will be funded by Cardiff University, with some funding awarded by Cancer Research Wales, and Oxford BioMedica will provide TroVax(R). The trial is supported by the Experimental Cancer Medicine Centre (ECMC), Cardiff.  

Ekahau Inc., a maker of high performance Wi-Fi-based Real Time Location Systems, today announced the launch of its newest Wi-Fi tag, the L4 Laptop tag. The L4 tag is a small flat unit designed to be plugged into the ExpressCard slot. The tag works with the Ekahau RTLS system which can track and manage the tags anywhere that has Wi-Fi coverage. 

Eurartesim(R) - dihydroartemisinin piperaquine (DHA-PQP) - the first artemisinin combination therapy (ACT) has been approved by the European Medicines Agency (EMA) for the treatment of uncomplicated malaria. Eurartesim was developed collaboratively by Sigma Tau Group, Italy, and the not-for-profit research foundation Medicines for Malaria Venture (MMV). 

 Eurartesim is now ready for delivery to Cambodia, the first malaria endemic country to place an order for the newly approved treatment. Cambodia prioritized the use of DHA-PQP as a first line drug and was awaiting EMA approval to allow procurement of this product using international donor funds. 

Mundipharma today announced the positive European Commission (EC) decision for flutiform(R) (fluticasone propionate/formoterol fumarate), a new combination therapy for the maintenance treatment of asthma, in Europe. This decision is binding on all 21 Concerned Member States involved in the decentralized procedure (DCP) and the first national approvals of flutiform are expected across a number of countries by the end of 2012.